Table 4.
Gender distribution of HOMA-IR cut-off levels, with their corresponding sensitivity and specificity,for classify of IDF MetS and ATPIII MetS, in diabetic and non-diabetic individuals
|
IDF criteria | ||||||
|---|---|---|---|---|---|---|
|
Population |
Criterion of specificity = 0.7 |
Youden index criterion |
||||
| Cut point | Sensitivity | Specificity | Cut point | Sensitivity | Specificity | |
| Diabetic |
|
|
|
|
|
|
| Men |
1.55 |
0.60 |
0.70 |
1.60 |
0.59 |
0.74 |
| Women |
2.22 |
0.37 |
0.70 |
1.58 |
0.68 |
0.46 |
| Non-diabetic |
|
|
|
|
|
|
| Men |
2.25 |
0.57 |
0.70 |
2.05 |
0.65 |
0.64 |
| Women* |
|
|
|
|
|
|
| 30 years |
2.11 |
0.77 |
0.70 |
2.31 |
0.71 |
0.76 |
| 50 years |
2.05 |
0.69 |
0.70 |
2.05 |
0.69 |
0.70 |
| 70 years |
2.38 |
0.45 |
0.70 |
2.53 |
0.40 |
0.75 |
|
ATP III criteria | ||||||
|
Population |
Criterion of specificity = 0.7 |
Youden index criterion |
||||
| |
Cut point |
Sensitivity |
Specificity |
Cut point |
Sensitivity |
Specificity |
| Diabetic |
|
|
|
|
|
|
| Men |
1.57 |
0.64 |
0.70 |
1.60 |
0.63 |
0.73 |
| Women |
2.22 |
0.37 |
0.70 |
1.58 |
0.68 |
0.46 |
| Non-diabetic |
|
|
|
|
|
|
| Men |
2.27 |
0.61 |
0.70 |
1.85 |
0.78 |
0.57 |
| Women* |
|
|
|
|
|
|
| 30 years |
2.12 |
0.79 |
0.70 |
2.36 |
0.73 |
0.77 |
| 50 years |
2.05 |
0.73 |
0.70 |
2.07 |
0.72 |
0.71 |
| 70 years | 2.37 | 0.48 | 0.70 | 2.47 | 0.44 | 0.74 |
*In non-diabetic females HOMA-IR cut-off values are estimated for 30, 50, and 70 years of age, because there is a non linear effect of age on test performance to classify IDF-defined MetS (P value < 0.001) and ATP III-defined MetS (P value = 0.012).
HOMA-IR, homeostasis model assessment of IR; ATPIII, Third Adult Treatment Panel; IDF, International Diabetes Federation; MetS, Metabolic Syndrome.